168 related articles for article (PubMed ID: 34981952)
21. High Gleason grade carcinoma at a positive surgical margin predicts biochemical failure after radical prostatectomy and may guide adjuvant radiotherapy.
Savdie R; Horvath LG; Benito RP; Rasiah KK; Haynes AM; Chatfield M; Stricker PD; Turner JJ; Delprado W; Henshall SM; Sutherland RL; Kench JG
BJU Int; 2012 Jun; 109(12):1794-800. PubMed ID: 21992536
[TBL] [Abstract][Full Text] [Related]
22. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.
Han M; Partin AW; Zahurak M; Piantadosi S; Epstein JI; Walsh PC
J Urol; 2003 Feb; 169(2):517-23. PubMed ID: 12544300
[TBL] [Abstract][Full Text] [Related]
23. Natural history of biochemical recurrence after radical prostatectomy with adjuvant radiation therapy.
Boorjian SA; Tollefson MK; Thompson RH; Rangel LJ; Bergstralh EJ; Karnes RJ
J Urol; 2012 Nov; 188(5):1761-6. PubMed ID: 22998913
[TBL] [Abstract][Full Text] [Related]
24. NADiA ProsVue prostate-specific antigen slope, CAPRA-S, and prostate cancer--specific survival after radical prostatectomy.
Moul JW; Sarno MJ; McDermed JE; Triebell MT; Reynolds MA
Urology; 2014 Dec; 84(6):1427-32. PubMed ID: 25432832
[TBL] [Abstract][Full Text] [Related]
25. The Impact of Downgrading from Biopsy Gleason 7 to Prostatectomy Gleason 6 on Biochemical Recurrence and Prostate Cancer Specific Mortality.
Ham WS; Chalfin HJ; Feng Z; Trock BJ; Epstein JI; Cheung C; Humphreys E; Partin AW; Han M
J Urol; 2017 Apr; 197(4):1060-1067. PubMed ID: 27847296
[TBL] [Abstract][Full Text] [Related]
26. Salvage High-Intensity Focused Ultrasound for Local Recurrence in the Prostatic Bed after Prostatectomy and Adjuvant or Salvage Radiotherapy: Preliminary Results.
Khedime S; Gelet A; Rouvière O; Lafon C; Badet L; Crouzet S; Hostiou T
J Urol; 2021 Aug; 206(2):325-337. PubMed ID: 33835863
[TBL] [Abstract][Full Text] [Related]
27. Impact of patient age on biochemical recurrence rates following radical prostatectomy.
Magheli A; Rais-Bahrami S; Humphreys EB; Peck HJ; Trock BJ; Gonzalgo ML
J Urol; 2007 Nov; 178(5):1933-7; discussion 1937-8. PubMed ID: 17868723
[TBL] [Abstract][Full Text] [Related]
28. Early localization of recurrent prostate cancer after prostatectomy by endorectal coil magnetic resonance imaging.
Linder BJ; Kawashima A; Woodrum DA; Tollefson MK; Karnes J; Davis BJ; Rangel LJ; King BF; Mynderse LA
Can J Urol; 2014 Jun; 21(3):7283-9. PubMed ID: 24978358
[TBL] [Abstract][Full Text] [Related]
29. Identification of Recurrence Sites Following Post-Prostatectomy Treatment for Prostate Cancer Using
Nehra A; Parker WP; Haloi R; Park SS; Mynderse LA; Lowe VJ; Davis BJ; Quevedo JF; Johnson GB; Kwon ED; Karnes RJ
J Urol; 2018 Mar; 199(3):726-733. PubMed ID: 28916273
[TBL] [Abstract][Full Text] [Related]
30. Predicting factors for progression to castration resistance prostate cancer after biochemical recurrence in patients with clinically localized prostate cancer who underwent radical prostatectomy.
Hashimoto T; Nakashima J; Kashima T; Yamaguchi Y; Satake N; Nakagami Y; Namiki K; Ohno Y
Int J Clin Oncol; 2020 Sep; 25(9):1704-1710. PubMed ID: 32500468
[TBL] [Abstract][Full Text] [Related]
31. Prediction of biochemical recurrence after radical prostatectomy with PI-RADS version 2 in prostate cancers: initial results.
Park SY; Oh YT; Jung DC; Cho NH; Choi YD; Rha KH; Hong SJ
Eur Radiol; 2016 Aug; 26(8):2502-9. PubMed ID: 26560721
[TBL] [Abstract][Full Text] [Related]
32. Reassessment of the risk factors for biochemical recurrence in D'Amico intermediate-risk prostate cancer treated using radical prostatectomy.
Narita S; Mitsuzuka K; Tsuchiya N; Koie T; Kawamura S; Ohyama C; Tochigi T; Yamaguchi T; Arai Y; Habuchi T;
Int J Urol; 2015 Nov; 22(11):1029-35. PubMed ID: 26290306
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of preoperative multiparametric magnetic resonance imaging (MRI) for predicting biochemical recurrence after radical prostatectomy.
Hattori S; Kosaka T; Mizuno R; Kanao K; Miyajima A; Yasumizu Y; Yazawa S; Nagata H; Kikuchi E; Mikami S; Jinzaki M; Nakagawa K; Tanimoto A; Oya M
BJU Int; 2014 May; 113(5):741-7. PubMed ID: 23937660
[TBL] [Abstract][Full Text] [Related]
34. Patterns and predictors of early biochemical recurrence after radical prostatectomy and adjuvant radiation therapy in men with pT3N0 prostate cancer: implications for multimodal therapies.
Briganti A; Joniau S; Gandaglia G; Cozzarini C; Sun M; Tombal B; Haustermans K; Hinkelbein W; Shariat SF; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):960-7. PubMed ID: 24351411
[TBL] [Abstract][Full Text] [Related]
35. PI-RADS Version 2 Category on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging Predicts Oncologic Outcomes in Gleason 3 + 4 Prostate Cancer on Biopsy.
Faiena I; Salmasi A; Mendhiratta N; Markovic D; Ahuja P; Hsu W; Elashoff DA; Raman SS; Reiter RE
J Urol; 2019 Jan; 201(1):91-97. PubMed ID: 30142318
[TBL] [Abstract][Full Text] [Related]
36. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy.
Trock BJ; Han M; Freedland SJ; Humphreys EB; DeWeese TL; Partin AW; Walsh PC
JAMA; 2008 Jun; 299(23):2760-9. PubMed ID: 18560003
[TBL] [Abstract][Full Text] [Related]
37. The significance of micro-lymphatic invasion and pathological Gleason score in prostate cancer patients with pathologically organ-confined disease and negative surgical margins after robot-assisted radical prostatectomy.
Hashimoto T; Nakashima J; Inoue R; Komori O; Yamaguchi Y; Kashima T; Satake N; Nakagami Y; Namiki K; Nagao T; Ohno Y
Int J Clin Oncol; 2020 Feb; 25(2):377-383. PubMed ID: 31673831
[TBL] [Abstract][Full Text] [Related]
38. Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy.
Fossati N; Karnes RJ; Cozzarini C; Fiorino C; Gandaglia G; Joniau S; Boorjian SA; Goldner G; Hinkelbein W; Haustermans K; Tombal B; Shariat S; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T; Briganti A
Eur Urol; 2016 Apr; 69(4):728-733. PubMed ID: 26497924
[TBL] [Abstract][Full Text] [Related]
39. Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database.
Mithal P; Howard LE; Aronson WJ; Kane CJ; Cooperberg MR; Terris MK; Amling CL; Freedland SJ
Int J Urol; 2015 Apr; 22(4):362-6. PubMed ID: 25728968
[TBL] [Abstract][Full Text] [Related]
40. Risk stratification of patients with extraprostatic extension and negative lymph nodes at radical prostatectomy: identifying optimal candidates for adjuvant therapy.
Eisenberg MS; Karnes RJ; Kaushik D; Rangel L; Bergstralh EJ; Boorjian SA
J Urol; 2013 Nov; 190(5):1735-41. PubMed ID: 23727312
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
